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What Can Comparative Effectiveness Research Contribute
to Integrative Health in International Perspective?
Claudia M. Witt, MD, MBA,1,2 Shelly Rafferty Withers, PhD,3 Suzanne Grant, PhD,4
Michael S. Lauer, MD,5 Sean Tunis, MD, MSc,6 and Brian M. Berman, MD3,7
Abstract
The interest in Comparative Effectiveness Research (CER) in the international community is growing. A
panel titled ‘‘What Can Comparative Effectiveness Research Contribute to Integrative Health in Interna-
tional Perspective?’’ took place at the 3rd International Research Congress on Integrative Medicine and
Health in Portland, Oregon, in 2012. The presentations at this panel highlighted different perspectives on
CER, including the funders’ and the stakeholders’ perspectives from the United States, as well as experi-
ences with economic evaluations from Australia and pragmatic trials in Europe. The funders’ perspective
emphasized the need for innovation and controlling costs in large-scale studies. The stakeholder’s per-
spective stressed the need to gather the input of stakeholders in shaping the framework for more informative,
more decision-maker-driven research. Several examples of cost-effectiveness analyses were offered from
Australia. The importance of balancing rigor and pragmatism was also discussed in a presentation of the
efficacy–effectiveness continuum. A wide-ranging discussion explored additional questions concerning the
translation of evidence into practice; the effect of pragmatic trials on funding or policy; evidentiary dis-
tinctions between and among pragmatic trials and traditional randomized clinical trials; and the multiple
roles of stakeholders, particularly in generating new information and knowledge. The presentations and
discussions showed that more development of methods is needed. This includes developments on study
design and statistical approaches, as well as methods for stakeholder involvement and mechanisms to bring
these results into practice.
Background
Despite the decades-long effort and the enormouseconomic and intellectual investments of clinical health
care researchers worldwide to provide solid evidence of the
efficacy and effectiveness of medications, therapies, inter-
ventions, and procedures, the randomized clinical trial (RCT)
has yielded relatively little ‘‘actionable intelligence’’ for
decision-makers. For patients, payers, caregivers, and pol-
icymakers, the evidence that has thus far been generated often
provides a strong endorsement of an intervention’s efficacy
(thus answering the question ‘‘Does it [the intervention] work
as we expected it to?’’), but fails to provide clarity for deci-
sion-makers confronted by choices between and among a
variety of options. Moreover, when an intervention has been
proven to ‘‘work,’’ it often does so in comparison to a pla-
cebo, only for an exclusive population of patients, and under
ideal, tightly controlled laboratory conditions. This rigor has,
unfortunately, largely provided results that are poorly gen-
eralizable and that require inordinate amounts of time and
financial resources to generate.1
In the early and mid-1990s, primarily in the United States,
the United Kingdom, and Germany, the methodologic con-
straints associated with the RCT became the focus of study
and experimentation. The concurrent emergence of interest
in examining the efficacy and effectiveness of comple-
mentary and alternative medicine interventions (driven by
the increasing use of complementary medicine medications,
approaches, and therapies), such as acupuncture, coincided
neatly with this methodologic curiosity. Some early
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studies,2–4 which broadened inclusion criteria and examined
a variety of outcomes, pointed to a new way of under-
standing the RCT, now known as pragmatic trials and seen
as an element of comparative effectiveness research (CER).5
CER evolved in the United States and pertains to research
that aims to generate evidence of critical importance to
decision-makers and succeeds by suggesting that flexibility
in study design offers researchers opportunities to sacrifice
some degree of internal validity in exchange for generating
results that are timely, and more generalizable, feasible, and
inclusionary than in traditional studies. Further, in the
conceptualization of research questions and study designs,
stakeholders—such as patients, patient caregivers, payers,
and policymakers—are invited into the process. Stakeholder
input emphasizes the sorts of questions and outcomes about
which decision makers require guidance.6
Integrative health care is a field particularly well suited for
CER investigations. Medicine is only one aspect of health,
and for future health care it is important to explore health
care with a wider view that also considers other aspects, such
as social and physical environment. The term ‘‘integrative
medicine’’ is widely used and has been defined by the
Consortium of Academic Health Centers for Integrative
Medicine as ‘‘the practice of medicine that reaffirms the
importance of the relationship between practitioner and pa-
tient, focuses on the whole person, is informed by evidence,
and makes use of all appropriate therapeutic approaches,
healthcare professionals and disciplines to achieve optimal
health and healing.’’7 The term ‘‘integrative health’’ is also
widely used but still needs a comprehensive definition.
Because it often concerns use of interventions from both
fields, conventional and complementary medicine in a ho-
listic effort to meet many patients’ needs (complicated by
comorbidities and comedications, particularly in treating
chronic disease), integrative health care points to patient
populations that are often excluded from traditional RCTs.
By fostering study designs that emphasize broader inclusion
criteria, more wide-ranging outcomes, subgroup analyses,
stakeholder input, usual care settings, and flexible treatment
protocols, CER has the potential to yield important evidence
for patients receiving integrative health care.8
The interest in CER is growing in the international com-
munity, and this article summarizes the presentations at a
panel titled ‘‘What Can Comparative Effectiveness Research
Contribute to Integrative Health in International Perspective?’’
The panel took place at the 3rd International Research Con-
gress on Integrative Medicine & Health in Portland, Oregon in
2012. It was jointly organized by the International Society for
Complementary Medicine Research and The Institute for In-
tegrative Health; contributors came from different continents
FIG. 1. The symposium
presenters. CER, Com-
parative Effectiveness
Research.
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and offered a variety of perspectives on CER, including the
funders’ and the stakeholders’ perspective from the United
States, as well as experiences with economic evaluations from
Australia and pragmatic trials from Europe (Fig. 1).
Presentations and subsequent discussion were recorded
and analyzed to provide a comprehensive paper that sum-
marizes the key points and provides some synthesized re-
sponses to additional issues with regard to CER.
Michael S. Lauer: The Funder’s Perspective on CER
The National Institutes of Health (NIH) budget has been
declining steadily since 2003; the budget continues to shrink.
Overall success rates for grant applicants are running at ap-
proximately 15%. Such financial conditions pose existential
threats for laboratories and require a considered re-evaluation
of priorities. Expensive clinical and epidemiologic studies are
not sustainable in the current funding climate; despite large,
supportive constituencies that recognize the essentiality of the
clinical research enterprise, fresh scrutiny of research impacts
is required.
Perspectives on this crisis vary, and it has even been
suggested that ‘‘ the NIH should not fund large clinical
studies that divert hundreds of millions of dollars away from
hypothesis-driven scientific research.’’9 Nonetheless, the
budgetary crisis presents a tremendous opportunity for
challenging communities that do epidemiologic and clinical
studies to change their business practices and explore new
models of clinical research design that drive generalizable,
meaningful results into the hands of decision-makers in a
timely and affordable fashion.
It is possible to do large-scale, high-impact trials at very
low cost. New technologies and tools, such as information
technology, mobile phone technologies, and electronic
medical records make it feasible to totally reinvent the
clinical trial enterprise. It’s not just aspirational—it abso-
lutely must be done.
Sean Tunis: The Involvement of Stakeholders
as an Important Aspect of CER
Dr. Sean Tunis discussed the development of effective-
ness guidance documents (EGDs) in an international con-
text. Much of the work has not taken place in the context of
integrative medicine, with the exception of the development
of an EGD for acupuncture research. The general model and
approach are very adaptable, particularly for integrative
medicine; generalizable; and important.
The whole methodologic framework of CER operates on
the premise that the engagement of the end users of research
results is stakeholder informed. The challenge is how to get
stakeholders and major decision-makers to align around
evidentiary expectations.
The American College of Physicians guideline has
identified—in the current and dominant framework of
conducting randomized trials—some methodologic deficiencies
(lack of comparative studies, outcomes that are not clinically
relevant, follow-up periods that are too short). Unfortunately,
neither that group nor any other has taken the next step to turn
these observations into good recommendations. In the case of
studies on Alzheimer disease, some areas that remain unre-
solved (1) the identification of appropriate comparators for new
drugs, (2) the identification of more appropriate and meaningful
outcomes, and (3) definitions of appropriate follow-up.
It is essential to explore the information needs of patient
advocacy groups, patients, and patient caregivers, but this is
clearly not enough. The stakeholders, including the payers,
can help shape the framework for more informative, more
decision-maker–driven research. In addition, however, reg-
ulators, the professionals with extensive experience in trial
design and methods, are required to translate these infor-
mation needs into guidelines that shape viable, methodo-
logically sufficient studies.
Design should be informed by stakeholder (patients and
clinicians) input but left up to the experts. From an inter-
national perspective, the Green Park Collaborative provides
a good example. The group was formed in London in 2011
to recommend study designs for researchers working on
Alzheimer disease. The group includes Francoise Meyer
(France), Sue Hill (Australia), Ryan O’Rourke (Canada),
Carole Longson (United Kingdom [National Institute for
Health and Care Excellence]), Finn Christenson (Denmark),
Paolo Siviero (Italy), and representatives from Singapore
and South Korea. The Green Park Collaborative also in-
cludes a patient-citizen representative and representatives
from the pharmaceutical industry.
The Green Park Collaborative is considering a recom-
mendation to include caregiver quality of life as a measure
of the effectiveness of Alzheimer drugs. Of course, regu-
lators would never consider incorporating these sorts of
measures. From a patient and family perspective, it is a
hugely important issue, and there are some validated ways
of looking at that.
This example provides one example of how methodologic
recommendations can be deployed to focus on high-priority
domains within integrative medicine. This group may well
take on additional topics in integrative medicine.
Suzanne Grant: The Options and Relevance of CER
Economic Evaluations, Including Cost Evaluations:
An Australian Perspective
In Australia, consumers directly pay for complementary
medicines, or, if the consumer is among the 51% who have
private health insurance, they may receive a partial rebate
for the product or practitioner service. Some limited gov-
ernment funding exists for therapies such as acupuncture,
osteopathy, and chiropractic. Since 1993, the Australian
government has required that cost-effectiveness must be
considered for any medicine to be publicly subsidized
through the Pharmaceutical Benefit Scheme or for any
treatment to be considered under Medicare. In When con-
sidering clinical effectiveness, data from head-to-head
comparative studies are preferred.
In the Australian context, limited data on the cost-
effectiveness and comparative effectiveness of comple-
mentary medicine and therapies are barriers to public
funding or support of these therapies.
The National Institute of Complementary Medicine has
conducted cost-effectiveness analyses of five complemen-
tary medicine interventions in the Australian context.
The complementary medicines and health conditions
were selected for study by a reference group if they met
such criteria as having a high burden (e.g., loss of quality of
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life, productivity, comorbidity), a clearly defined interven-
tion with adequate comparative effectiveness evidence
available, and a well-defined comparator or standard treat-
ment. The interventions selected were acupuncture for
chronic low back pain; St. John’s wort for mild-to-moderate
depression; fish oils for prevention of heart disease among
patients who have experienced myocardial infarction; fish
oils for rheumatoid arthritis; and a proprietary product,
Phytodolor (a tree bark and plant extract from Populus
tremula, Fraxinus excelsior, and Solidago virgaurea), for
osteoarthritis.
Cost-effectiveness of the interventions was determined
through meta-analyses. Costs were calculated on the stan-
dard cost for an acupuncture consultation and standard
costs for fish oils. The analysis assessed how much the
treatment reduced health care system costs through reduced
adverse events. Only the direct health system costs were
included in each analysis. Indirect costs, such as absen-
teeism and carer costs, were excluded. Results were ex-
pressed as cost per disability-adjusted life-year (DALY).
Parameters were defined for mortality, morbidity, and ad-
verse events for each disease. A sensitivity analysis was
conducted for each intervention to take into account dif-
ferent parameters.
World Health Organization guidelines were used to define
a cost effective intervention. These guidelines articulate
cost-effectiveness in terms of the cost to reduce disease
burden by 1 DALY. The number of DALYs lost because of
a disease is calculated according to mortality and morbidity
of the disease. For each intervention, the costs and benefits
associated with that strategy were compared with another
treatment, such as standard care. A treatment may be con-
sidered cost-effective if the cost is one to three times the
gross domestic product (GDP) per capita per DALY averted
($52,000AUD to $56,000AUD in 2009), while interventions
costing less than 1 GDP per capita ($52,000AUD) per DALY
averted are deemed very cost-effective. The GDP per capita in
Australia was $52,000AUD in 2008–2009.
This cost-effectiveness analysis method was selected for
two reasons. First, cost-effectiveness analyses compare rel-
ative costs and outcomes of two or more courses of action.
The denominator is nonmonetary (gain in health measured
as a DALY avoided) and the numerator is monetary (cost of
the health gain). Second, sufficient evidence was available
for some complementary medicines to meet the assumptions
needed to complete a cost-effectiveness analysis.
For the first intervention, acupuncture for chronic low
back pain, three scenarios were explored. For acupuncture
and standard care versus standard care and sham, only two
studies were suitable for inclusion. A weak positive effect
was found for weeks 12–16, but the difference was not
significant; thus, a cost-effectiveness analysis was not con-
ducted. For acupuncture and standard care versus standard
care alone, acupuncture was very cost-effective, costing less
than $52,000AUD. In a sensitivity analysis, when depres-
sion was included, further savings were generated, and the
intervention costs $19,000AUD per DALY averted. For
acupuncture versus standard care, acupuncture was not
generally cost-effective unless comorbid depression was
relieved; if that occurred, then the cost per DALY averted
was $62,946AUD—and therefore acupuncture was consid-
ered cost-effective.
In two meta-analyses, St. John’s wort (SJW) was as ef-
fective as standard antidepressants for mild-to-moderate
depression.10,11 It was just as safe and effective as standard
care; it had lower levels of adverse effects and fewer patient
withdrawals from treatment. On the basis of these meta-
analyses, treatment with St. John’s wort rather than standard
antidepressants may result in a reduction of $146 per patient
per year. The total savings would depend on current utili-
zation data and on whether both mild and moderate de-
pression was treated. The main driver of this result was that
the unit cost of St. John’s wort was estimated as $0.17/day
while the cost of standard antidepressants was estimated as
$0.57/day. Standardization of a St. John’s wort product may
add costs.
Fish oil use among patients who have experienced a re-
cent myocardial infarction is thought to prevent further
cardiovascular disease, although recent research has brought
this into dispute.12 This cost-effectiveness analysis, con-
ducted before this recent research, looked at the value of
complementing standard care for patients who have had a
myocardial infarction with omega-3 fish oil supplements;
fish oil supplements were introduced within 3 months of
myocardial infarction. Fish oils were highly cost-effective,
even with sensitivity analyses on treatment variables (such
as myocardial infarction, stroke, revascularization, coronary
heart disease mortality, and other mortality). The total cost
to administer fish oil to all patients with coronary heart
disease is around $40 million per year, with approximately
19,000 DALYs averted.
The fourth cost-effectiveness analysis examined the
cost-effectiveness of using fish oil supplements as an ad-
junctive therapy for rheumatoid arthritis (with lower non-
steroidal anti-inflammatory drug [NSAID] use) rather than
standard NSAID therapy alone. The meta-analysis found
that fish oil use can lead to long-term reductions in NSAID
reliance, but systematic inclusion of fish oils as a main-line
intervention for rheumatoid arthritis does not seem eco-
nomically justified.
The last cost-effectiveness analysis, which dealt with
Phytodolor for managing the pain and inflammation of
osteoarthritis, lacked adequate data for a meta-analysis.
The short timeframes for the studies; differences in study
design, comparators, and outcome measures; and dif-
ferences in dosages made a meta-analysis difficult. Phy-
todolor has a good safety profile compared with that of
cyclo-oxygenase-2 inhibitors and has been found to be as
effective as diclofenac.
The five economic evaluations reported contribute to a
small but growing body of evidence on the cost-effectiveness
of complementary medicine interventions. The methods
used in these five cost-effectiveness analyses have some
limitations but offer sufficient rigor. The noninclusion of
indirect cost is likely to have rendered more conservative
conclusions.
Claudia M. Witt: The Efficacy and Effectiveness
Continuum in Clinical Trials: Between Rigor and
Pragmatism in Clinical Trials—A European Perspective
To improve understanding of the early acupuncture trials
in Europe and the efficacy-effectiveness continuum, it is
helpful to consider some fundamental definitions. Efficacy is
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defined by the extent to which a specific intervention,
procedure, regimen, or service produces a beneficial result
under ideal conditions. Ideally, the determination of effi-
cacy is based on the results of an RCT—a typical drug trial
would be the best example—in which the protocols are
standardized and the inclusion criteria are very narrow.13
By contrast, effectiveness is a measure of the extent to
which a specific intervention, procedure, regimen, or ser-
vice, when deployed in the field in the usual circum-
stances, does what it is intended to do for a specified
population.13
In clinical research, effectiveness on a high evidence level
is best demonstrated by pragmatic trials.5 In a pragmatic
trial, patients usually seen in normal practice are represented
in the study population and the treatment protocol allows
more flexibility. It is crucial to understand that efficacy and
effectiveness are at opposite poles of a continuum. Any
study can be placed somewhere along this continuum—and
only few studies are at one or the other extreme. Where a
study is placed depends on the details of the study design. In
this context, four dimensions of the study design play an
important role: eligibility criteria, treatment protocol, out-
comes, and study context.
To assist researchers in working their way through the
twists and turns of designing CER studies, EGDs) are be-
ing developed. The protracted and robust discussions that
have accompanied working groups’ efforts to develop
EGDs enrich the final products. The discussions are char-
acterized by much negotiation between and among scien-
tists, practitioners, patients, and payers. The EGD on
acupuncture that has been developed thus far provides very
detailed guidance on methodologic issues in designing
CER on acupuncture.14
Integrative medicine has contributed to CER. Sean Tu-
nis’s landmark paper in JAMA in 2003 moved thinking in
conventional medicine forward.1 The early pragmatic
trials on acupuncture took place in the United Kingdom
and started patient recruitment in 1999,2,15–18 followed by
large acupuncture trials in Germany, in which patient re-
cruitment began in 2001.4,19,20 Acupuncture was always
provided in addition to usual care to a broad patient
population, allowing an individualized treatment in a
usual care context. Interestingly, all pragmatic acupunc-
ture trials in Germany and the United Kingdom were ac-
companied by cost-effectiveness evaluations, showing
that an additional acupuncture treatment was relatively
cost-effective within international thresholds. That acu-
puncture research is a spearhead for integrative medicine
in the field of CER is also supported by a systematic re-
view on acupuncture for low back pain, which concluded
that existing acupuncture trials already contribute to
CER.21 Other fields of integrative medicine can learn from
this experience.
Discussion
Discussion with the audience was wide-ranging and fo-
cused primarily on the effect of pragmatic trials on funding
or policy; evidentiary distinctions between and among
pragmatic trials and traditional RCTs; and the multiple roles
of stakeholders, particularly in generating new information
and knowledge.
The impact on funding policy
The discussion highlighted that important decisions are
often made with very little evidence. Further, having evi-
dence does not mean that such evidence is translated into
practice. The pragmatic acupuncture trials in Germany had
no impact on reimbursement decisions. In Germany, the fact
that acupuncture is reimbursed for chronic low back pain
and osteoarthritis pain was based solely on trials that also
included sham acupuncture arms. By contrast, in the United
Kingdom, the pragmatic trial on low back pain had a posi-
tive effect on National Health Service coverage.
Examples from conventional medicine in which results
from CER did not change practice were also offered. The
most prominent example was the Antihypertensive and
Lipid Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT).22 ALLHAT, the largest and most important
clinical trial in hypertension ever done in the United States,
demonstrated that a diuretic was as effective as a calcium
antagonist, an angiotensin-converting enzyme inhibitor, and
an a-adrenergic blocker; there was no change in clinical
practice.
Type of evidence
The hierarchy of evidence and what constitutes sufficient
evidence to change a national coverage policy—in the United
States or Europe—has often been tied to a high level of
certainty as to whether a particular treatment was effective for
a specific patient population. However, as payment reform
takes hold, and the risk is delegated from private payers alone
to a risk shared by providers and patients, it is likely that a
wider range of evidence will be considered sufficient.
While some discussants were concerned that CER studies
with multiple comorbidities and comedications might weaken
measures of effectiveness, it was suggested that subgroup
analyses in pragmatic trials will require a larger sample size
because there will be more variance in the data. Conse-
quently, a larger sample size is needed to obtain a meaningful
statistical difference. Exploratory analysis also offers an op-
portunity to generate hypotheses.
Participants in the discussion acknowledged that the pre-
senters had not addressed observational studies. The partici-
pants noted that with randomized clinical trials, we regard the
evidence as more or less on the ‘‘safe side’’; we have con-
fidence in the method. Yet in observational studies, more
methodologic development is necessary to ensure the reli-
ability of the evidence such studies generate. Some devel-
opment is underway, but more work is needed in this area.
Stakeholder involvement
In cases where it’s essentially impossible to give defini-
tive, reliable, accurate, and precise information to patients
about risks and benefits for alternatives, and for decisions in
which uncertainty exists, the collaboration attempts to
identify and explore the decision points associated with the
highest levels of uncertainty. A knowledge-generating en-
terprise is needed to address the questions that stakeholders
confront in the face of rising health care insurance and other
health care costs. Relevant, useful, accurate information is
needed—the sort of information that the evidence-generat-
ing, consumer-driven CER agenda will produce.
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The role of stakeholders in this process was seen as
critical. It is essential to leverage patient insights in the
decision-making process to inform the design and im-
plementation of better information. Shared decision-making
processes can act as an input into evidence generation. A
remaining challenge in this domain is in communicating
across a variety of stakeholder communities who don’t
speak the same language. In addition to developing a
common language and understanding of each community’s
point of view, these conversations must take place because
they highlight each community’s vested interests, access (or
lack thereof), and priorities. The conversations also build
trust and provide the mechanism in which negotiations and
information-sharing can take place. As an example, the Center
for Medical Technology Policy is collaborating with the
Foundation for Informed Medical Decision-Making (which
develops shared decision-making programs based on multiple
focus groups with patients) to deeply understand what the
alternatives are and to help patients make informed decisions.
Another organization that supports patient-centeredness and
stakeholder engagement is the Patient-Centered Outcomes
Research Institute, which ‘‘helps people and their caregivers
communicate and make informed health care decisions,
allowing their voices to be heard in assessing the value of
health care options’’.23
Methods development
From the methodologic perspective, two points were
highlighted: Some value was seen in study designs that
consider patient preferences (e.g., two-stage randomized
trial designs) and the need to develop these designs further.
In addition, a strong need for innovation among statisticians
to take up the challenge to solve the ‘‘right problem’’—
instead of the easy solution to a pristine problem—was
considered essential. Stronger and more robust interactions
with statisticians and nonstatisticians are also encouraged.
Conclusion
From the presentations and discussions, it became clear
that even as more pragmatic trials and studies are published,
more methods development is needed. This includes de-
velopments on study design and statistical approaches, as
well as methods for stakeholder involvement and mecha-
nisms to bring these results into practice. In the United
States, the Patient-Centered Outcomes Research Institute is
devoting a substantial percentage of its budget to the de-
velopment of methods and tools for CER. Development of
these tools is critical to advancing the entire CER agenda.
However, other countries, such as Australia and Germany,
have not yet developed these mechanisms.
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